0.0001  0 (0%)		06-18 20:00
Open: 0.0001 High: 0.0001 Volume: 150		Pre. Close: 9.9999997E-5 Low: 0.0001 Market Cap: 0(M)

Short term
Mid term
Targets	6-month :	0	1-year :	0
Resists	First :	0	Second :	0
Pivot price	0
Supports	First :	0	Second :	0
MAs	MA(5) :	0	MA(20) :	0
	MA(100) :	0	MA(250) :	0.08
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	1	D(3) :	0
RSI	RSI(14): 16.7
52-week	High :	0.32	Low :	0

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ PXMD ] has closed Bollinger Bands are 100% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 69 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	0 - 0	0 - 0
Low:	0 - 0	0 - 0
Close:	0 - 0	0 - 0

PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms. The company's lead product candidate is PAX-101, an intravenous formulation of suramin for various indications, including autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, and human african trypanosomiasis. It is also involved in developing PAX-102, an intranasal formulation of suramin for neurologic indications. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York. PaxMedica, Inc. operates as a subsidiary of Tardimed Sciences LLC.

Fri, 13 Jun 2025
PaxMedica Renames to Kuvatris, Cancels Shares - TipRanks

Fri, 04 Apr 2025
PaxMedica announces board resignations amid transition - Investing.com

Mon, 20 Jan 2025
PaxMedica Secures Immediate Exercise of Warrants - ACCESS Newswire

Sat, 04 May 2024
PXMD Stock Price and Chart — OTC:PXMD - TradingView

Mon, 20 Nov 2023
Why Is PaxMedica (PXMD) Stock Down 40% Today? - InvestorPlace

Wed, 28 Dec 2022
3 Short Squeeze Penny Stocks To Watch Before 2023 - PennyStocks.com

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: OTC
Sector: Healthcare
Industry: Biotechnology
Shares Out	8 (M)
Shares Float	7 (M)
Held by Insiders	12.6 (%)
Held by Institutions	0 (%)
Shares Short	638 (K)
Shares Short P.Month	552 (K)

EPS	68.22
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.15
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-258.3 %
Return on Equity (ttm)	-975.1 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	-11 (M)
Levered Free Cash Flow	-5 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	-0.01

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.